ArticleThe Journal of infectious diseases2010
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy.
Article in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Platelet activation in adult HIV-infected patients on antiretroviral therapy: a systematic review and meta-analysis.BMC medicine · 2020Pooled it
- Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens.Frontiers in immunology · 2024Trial
- Interleukin 6 Blockade With Tocilizumab Diminishes Indices of Inflammation That Are Linked to Mortality in Treated Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.Antiviral therapy · 2018Trial
- Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.EBioMedicine · 2016Trial
- HIV vasculopathy: role of mononuclear cell-associated Krüppel-like factors 2 and 4.AIDS (London, England) · 2015Trial
- Pre-therapy inflammation and coagulation activation and long-term CD4 count responses to the initiation of antiretroviral therapy.HIV medicine · 2015Trial
- Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy.Journal of acquired immune deficiency syndromes (1999) · 2015Trial
- Trial
- Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study.BMC infectious diseases · 2014Trial
- Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.Journal of acquired immune deficiency syndromes (1999) · 2014Trial
- Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Trial
- Trial
- Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.The Journal of infectious diseases · 2011Trial
- Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial.AIDS (London, England) · 2011Trial
- Serum Interleukin-6 and Interleukin-10 levels in people living with HIV on short-term and long-term antiretroviral therapy: a comparative cross-sectional study with HIV-negative controls.BMC infectious diseases · 2026Article
- The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.Open forum infectious diseases · 2025Article
- The Potential ofCells · 2022Review
- Periods of Homelessness Linked to Higher VACS Index Among HIV-Positive People Who Use Drugs.AIDS and behavior · 2022Article
- Cannabinoids: Therapeutic Use in Clinical Practice.International journal of molecular sciences · 2022Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundTo identify inflammatory pathways that may contribute to the pathogenesis of human immunodeficiency virus (HIV) disease, we explored associations between AIDS or death and different inflammatory markers, including selected soluble tumor necrosis factor superfamily receptors (sTNFRs) and ligands, interleukin (IL)-6, and CD8 T cell activation, in individuals treated with highly active antiretroviral therapy (HAART).
methodsA case-control study of subjects in AIDS Clinical Trials Group (ACTG) protocols 384 and 5015, who were matched according to the CD4 cell count and plasma viral load at baseline, was performed using conditional logistic regression.
resultsHigher pretreatment concentrations of sTNFR-1, sCD27, sCD40L, and plasma IL-6 were associated with a new AIDS-defining illness or death in separate models adjusted for age, sex, hemoglobin, and the latest CD4 cell counts. In additional models that excluded case patients with opportunistic infections, sTNFR-1, sCD27, and sCD40L were each associated with a new AIDS-defining malignancy or death that developed at a median of 51 weeks after initiation of HAART, by which time the majority of subjects had a CD4 cell count of >200 cells/cm(3) and had achieved a plasma viral load of <50 copies/mL.
conclusionThese data are compatible with a model in which these soluble inflammatory markers identify pathways that may contribute to the pathogenesis of HIV disease progression, pathways that might not be a direct consequence of ongoing HIV type 1 replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.